Talazoparib (BMN 673)

For research use only.

Catalog No.S7048 Synonyms: LT-673

122 publications

Talazoparib (BMN 673) Chemical Structure

CAS No. 1207456-01-6

Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) CAD 298 In stock
CAD 592 In stock
CAD 1785 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Talazoparib (BMN 673) has been cited by 122 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.
Features Most potent and selective PARPi reported thus far.
Targets
PARP1 [1]
(Cell-free assay)
0.57 nM
In vitro

BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. BMN 673 selectively kills cancer cells with BRCA-1 or BRCA-2 mutations. BMN 673 demonstrates single-agent cytotoxicityin BRCA-1 mutant (MX-1, IC50 = 0.3 nM) and BRCA-2 mutant cells (Capan-1, IC50 = 5 nM). In contrast, in MRC-5 normal human fibroblastand other tumor cell lines with wild-type BRCA-1 and BRCA-2 genes, IC50 of BMN 673 ranges between 90 nM and 1.9 μM. [1] In cultured human cancer cells, BMN 673 also significantly enhances the cytotoxic efficacy of both Temozolomide and SN-38. Off-target molecular screening did not identify significant non-specific activity for this class of PARP inhibitors. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BR5FVB1-Akt NEHQXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HFVlAvOS1zMECgcm0> MlW2NlQwPDhxN{KgbC=> NILad3VqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDk[ZBmdmSnboTsfS=> NUHXcYw5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFc3QTdpPkK2NFQ4Pjl5PD;hQi=>
BR5FVB1-Akt NVnrb4dnSXCxcITvd4l{KEG|c3H5 NH7HVWExNjFvMUCwJI5O NWPqZm5FPzJiaB?= MUDpcoR2[2W|IHHwc5B1d3Orcx?= M3XydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES3Olk4Lz5{NkC0O|Y6PzxxYU6=
Capan-1 NE\xXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvZe5dKSzVyPUG2MlDjiIoEsfMAjVUvPOLCidM1UeKh NEjwNHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2OFU6OCd-MkW4OlQ2QTB:L3G+
MIA PaCa-2 NVHyZ4R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnjTWM2OD13OD6yN-KBkcLz4pEJPE4y6oDLwsXNxsA> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NEW5NEc,OjV6NkS1PVA9N2F-
RD MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HkeGlEPTB;OD63JI5O MlrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
Rh41 NYjvT414T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7s[ppGUUN3ME24MlEhdk1? MknCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
Rh18 MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrYTVNKSzVyPUSuPUBvVQ>? M3PrclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
Rh30 NWj1VVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPmNJZGUUN3ME2zNU4yKG6P MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
BT-12 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvWfYk2UUN3ME9ihKkyNDByMDDuUS=> NVLIeXp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
CHLA-266 NGLwZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRuLCiUGsNFAxKG6P NX74THBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
TC-71 NYGwdIdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTpTWM2OD1|Lkegcm0> NHrXNGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
CHLA-9 NYLHSnlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvtWJZ1UUN3ME24MlIhdk1? MlvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
CHLA-10 NYjtR4tiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTZ5Lkigcm0> MmnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
CHLA-258 M3z0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:zNnNKSzVyPUSuOkBvVQ>? NIDYWnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
SJ-GBM2 M3jBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLlXJpZUUN3ME2xOk4zKG6P NWjLUHc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
NB-1643 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon0TWM2OD1zOD60JI5O M1vWWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
NB-EBc1 NH75cplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfJSlROUUN3ME2yOU45KG6P M{LudFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
CHLA-90 NY\N[|ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvYenZxUUN3ME9ihKkyNDByMDDuUS=> NHP6O3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
CHLA-136 M2PGVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXPXVhnUUN3ME2xOE4zKG6P NUjQeYNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
NALM-6 NVLNZVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXWNoZKSzVyPUS5JI5O MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
COG-LL-317 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljGTWM2OD17LkSgcm0> NILRN|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
RS4;11 Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXRc4hKSzVyPUWyMlYhdk1? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
MOLT-4 NXrTSlNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\vNohmUUN3ME2xOk43KG6P MnnSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
CCRF-CEM M33tR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkToTWM2OD14OUeuN{BvVQ>? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
Kasumi-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\rW5VKSzVyPUe4Ok4zKG6P M3nEb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
Karpas-299 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S3VGlEPTB;N{WuO{BvVQ>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
Ramos-RA1 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZ6LkOgcm0> Mli4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
DT40 MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrs[FZKSzVyPUSgcm0> NHzJ[FQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1OlgyOyd-MkSzOVY5OTN:L3G+
DU145 NGnzZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rPR2lEPTB;MUGgcm0> NFTaWlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1OlgyOyd-MkSzOVY5OTN:L3G+
H209 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jORWlEPTB;MT63JI5O M17lZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
H1048 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJwMjDuUS=> MmftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyN{ezOVAoRjJ2MEe3N|UxRC:jPh?=
H524 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzXN4lWUUN3ME2zMlEhdk1? M3nPOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
H1930 NVfDeGxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVruZldbUUN3ME20MlEhdk1? M2rjS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
H69 M4\xV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHjTWM2OD13LkKgcm0> M4LmNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
H2081 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTzTWM2OD14LkOgcm0> M4LFRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
H2107 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LT[WlEPTB;Nz6zJI5O M1jT[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
H1092 M4mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG4fZZKSzVyPUiuPUBvVQ>? M2rhSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
DMS-79 M3rMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXCXVBKSzVyPUmuN{BvVQ>? NHWz[VI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC3O|M2OCd-MkSwO|c{PTB:L3G+
H446 M1;QSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnUO5dtUUN3ME2xN{BvVQ>? NGD0SVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC3O|M2OCd-MkSwO|c{PTB:L3G+
COR-L279 NF3xWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:3eno3UUN3ME2xOUBvVQ>? MlPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyN{ezOVAoRjJ2MEe3N|UxRC:jPh?=
LoVo MnvCSpVv[3Srb36gZZN{[Xl? NIfaUIM{OCCvaX7z M13kW2VEPTBiPTCwMlAxOjVizszN NEf3eGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVA6Pid-MkW3OlExQTZ:L3G+
MX1 MlHUR5l1d3SxeHnjbZR6KGG|c3H5 NYjOb3FITUN3MDC9JFAvODByMzFOwG0> M{jLTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
LoVo NVz6THJ1TnWwY4Tpc44h[XO|YYm= MkjTN|AhdWmwcx?= NUT2Rm5RTUN3MDC9JFAvODB{NUGg{txO NWHxdmNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
LoVo M3vjZmN6fG:2b4jpZ4l1gSCjc4PhfS=> Mlm4NE41KHWP M4\NXlUh\GG7cx?= MYXHTVUxKD1iMD6wNFQh|ryP NHXVeoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
Capan1 Mn3HR5l1d3SxeHnjbZR6KGG|c3H5 NEj3fXlGSzVyIE2gNE4xODVizszN NF3CO2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MRC5 MmDlR5l1d3SxeHnjbZR6KGG|c3H5 M4DjZWVEPTBiPTCwMlMyKM7:TR?= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
MX1 NEi3WW9HfW6ldHnvckBie3OjeR?= M4\wblEhdWdxa3e= MmLXNkAtQCCjbnSgNlQhcHK| Mn:3SIVkemWjc3WgbY4hWEGUIHzleoVtKGmwIHH0bJlucWNiboWvcpUhdW:3c3WgfIVvd2e{YX\0[YQhf2m2aDDoeY1idiCPWEGgZ4VtdHNiYYSgNUBu\y:tZzygdI8h[WSvaX7pd5RmemWmIHHzJJNqdmeuZTDkc5NmKG2nYYP1doVlKGGodHXyJFIhNDhiYX7kJFI1KGi{czDifUBGVEmVQR?= NYnxZ|hvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
MX1 NUTCbnkxSW62aYT1cY9zKGG|c3H5 M3vISFAvOzNibXevb4c> NXi3UW1qOjhiZHH5dy=> MU\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDCVmNCOSCmZX\pZ4lmdnRiaIXtZY4hVVhzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpUwdnVibX;1d4Uh[XRiMD6zN{Bu\y:tZzygdI8heWRiYXTtbY5qe3SncnXkJIZweiB{ODDkZZl{ M2Xxd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MX1 Ml7yRY51cXS3bX;yJIF{e2G7 MXuwMlE3PSCvZz;r[y=> NVTzTXR6OjhiZHH5dy=> M2ri[2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGJTS0FzIHTl[olkcWWwdDDoeY1idiCPWEGgZ4VtdHNieHXuc4dz[W[2ZXSgbY4h[XSqeX3pZ{BvfS:wdTDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCwMlE3PSCvZz;r[{wheG9iYXTtbY5qe3SncnXkJJR4cWOnIHGg[IF6KG[xcjCyPEBl[Xm| NG[wT|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MX1 MoniSpVv[3Srb36gZZN{[Xl? MV6wMlM{KG2pL3vn MnzaVI91\W62aXH0bY9vKG:oIHPhdoJweGyjdHnuMYlv\HWlZXSgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25ib3[gRnJESTFiZHXmbYNq\W62IHj1cYFvKE2[MTDj[YxteyC6ZX7v[5Ji\nSnZDDpckBifGi7bXnjJI52N263IH3veZNmKGG2IECuN|MhdWdxa3egdI8h[W6mIHHubY1idHNid3Xy[UB1emWjdHXkJJdqfGhiY3HyZo9xdGG2aX6gZZQhOzVibXevb4ctKGmyIH;uJIRigSBz M3HYXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MDA-MB-436 NHT4RZpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MoDjO{Bl[Xm| NV3LTIc6UUN3MDC9JFAvODByNzFOwG0> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ7MkmxOkc,Ojh4OUK5NVY9N2F-
Capan1 MXLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M2rwV|ch\GG7cx?= NV7lW5NUUUN3MDC9JFAvODBzODFOwG0> MnrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OUK5NVYoRjJ6NkmyPVE3RC:jPh?=
VC8 MWXDfZRwfG:6aXPpeJkh[XO|YYm= NIjROGw{KGSjeYO= M{\qdmlEPTBiPTCwMlAxPDJizszN M4HtXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkmyPVE3Lz5{OE[5NlkyPjxxYU6=
V79 Ml;0R5l1d3SxeHnjbZR6KGG|c3H5 MmXUN{Bl[Xm| NX\HdJo{UUN3MDC9JFUvODFzNDFOwG0> Mkf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OUK5NVYoRjJ6NkmyPVE3RC:jPh?=
Capan1 M2HPT2Z2dmO2aX;uJIF{e2G7 NXzYVGxLOC5zIIXN NGT0W401KGi{cx?= NXrPellQUW6qaXLpeIlwdiCxZjDQRXJROSCrbjDCVmNCOiCmZX\pZ4lmdnRiaIXtZY4hS2GyYX6xJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFCDUmCxMWRPSSC2cnHwdIlv\yCjdDCwMlEhfU1iYX\0[ZIhPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ7MkmxOkc,Ojh4OUK5NVY9N2F-
MDA-MB-436 NXrZSYx3TnWwY4Tpc44h[XO|YYm= MXSxJJVO NFf2ZmM1KGi{cx?= NH7yNGFKdmirYnn0bY9vKG:oIGDBVnAyKGmwIFLSR2EyKGSnZnnjbYVvfCCqdX3hckBOTEFvTVKtOFM3KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIGDBVnAyNUSQQTD0doFxeGmwZzDheEAyKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= M1LUWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkmyPVE3Lz5{OE[5NlkyPjxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved-PARP / cleaved-caspase3 / γ-H2AX; 

PubMed: 29158830     


Western Blot data testing protein expression after treatment with Olaparib, Niraparib, and Talazoparib on Brca1-deficient cell line in W0069 cells.

pKAP1 / pChk2 / pChk1; 

PubMed: 28947502     


Western blot images (representative from 3 independent experiments) showing the impact of a 24 hour pre-treatment with TAL ± TMZ on DNA damage signaling in U251 (MGMT-low) and T98G (MGMT-high) cells. 

PD-L1; 

PubMed: 28167507     


MDA-MDA-MB-231 and BT549 cells were treated with 10 μM olaparib or 10 nM talazoparib for 24 hours, and subjected to immunoblotting with the indicated antibodies. PD-L1 knockout (K/O) cells were included as a negative control. 

p-ATM; 

PubMed: 30472087     


Western blot analysis of the DNA damage sensors ATM, p-ATM (Ser1981), CHK1, p-CHK1 (Ser317), CHK2 and p-CHK2 (Thr68) in MV4-11 and HL-60 cells. GAPDH served as a loading control.

29158830 28947502 28167507 30472087
Growth inhibition assay
Cell viability; 

PubMed: 29158830     


Measured dose response curve and IC50 of Talazoparib in W780 and W0069 cells.

29158830
Immunofluorescence
cleaved PARP / 53BP1; 

PubMed: 28958991     


Cleaved-PARP and 53BP1 expression. Representative images with 10× objective from high-content imaging of control cells in the left column, and cells treated with veliparib, olaparib, and talazoparib in three right columns. 53BP1 expression is seen in: A, HCC1143; B, MDAMB231; and C, HCC1806. Blue represents nuclear staining and pink foci represent 53BP1 foci. Cleaved-PARP expression is seen in D, HCC1143 and E, HCC1806. Blue represents nuclear staining and green represents cleaved-PARP expression.

RAD51; 

PubMed: 30621214     


(A) MCF7 and (B) MCF7-T cells were treated with either 100 nM tamoxifen (Tamox) or 1 nM talazoparib (Talaz) for 72 h, alone and in combination. 24 h post treatment RAD51 foci formation assay was performed. Scale bar: 20 µm.

28958991 30621214
In vivo In rat pharmacokinetic studies, BMN 673 displays >50% oralbioavailability and pharmacokinetic properties that enable singledaily dosing. In MX-1 xenograft tumor model studies, daily oral dosingof BMN 673 significantly enhances the antitumor effects ofcytotoxic therapies in a dose-dependent manner. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: MX-1 model (BRCA-1 deficient)
  • Dosages: 0.33 mg/kg/day, once daily
  • Administration: Oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL warmed (99.9 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 380.35
Formula

 

C19H14F2N6O
 
CAS No. 1207456-01-6
Storage powder
in solvent
Synonyms LT-673
Smiles CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04692662 Not yet recruiting Drug: talazoparib Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 8 2021 Phase 2
NCT04672460 Not yet recruiting Drug: TALZENNA capsule|Drug: Talazoparib soft gel capsule Advanced Solid Tumors Pfizer December 2020 Phase 1
NCT04497116 Recruiting Drug: RP-3500|Drug: Talazoparib: oral PARP inhibitor Advanced Solid Tumor Adult Repare Therapeutics July 22 2020 Phase 1|Phase 2
NCT04337970 Recruiting Drug: Talazoparib|Drug: Axitinib Kidney Cancer|Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma Memorial Sloan Kettering Cancer Center April 6 2020 Phase 1|Phase 2
NCT04134884 Recruiting Drug: Talazoparib|Drug: ASTX727 Metastatic Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Tumor Kathy Miller|Pfizer|Astex Pharmaceuticals Inc.|Van Andel Institute Stand Up to Cancer Team|Indiana University March 30 2020 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Which solvent do you recommend to dilute the inhibitor for in vivo study in mice?

  • Answer:

    BMN673 (S7048) can be dissolved in vehicle (10% DMAc, 6% Solutol, and 84% PBS) according to the paper: http://clincancerres.aacrjournals.org/content/19/18/5003.full. Quote from Method and Material section "Xenograft experiments: BMN 673 (various doses as indicated), or vehicle (10% DMAc, 6% Solutol, and 84% PBS) was administered by oral gavage"

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Talazoparib (BMN 673) | Talazoparib (BMN 673) supplier | purchase Talazoparib (BMN 673) | Talazoparib (BMN 673) cost | Talazoparib (BMN 673) manufacturer | order Talazoparib (BMN 673) | Talazoparib (BMN 673) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID